News & Updates
Filter by Specialty:
Novel drug helps optimize HFrEF therapy
In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.
Novel drug helps optimize HFrEF therapy
27 Apr 2022
Intensive urate lowering of little benefit to patients with erosive gout
A more intensive serum urate-lowering therapy falls short of improving bone erosion scores in patients with erosive gout, in addition to being associated with a high treatment burden, as shown in a study.
Intensive urate lowering of little benefit to patients with erosive gout
27 Apr 2022
Novel drug promising for paediatric Tourette syndrome
The experimental drug ecopipam helps minimize motor and phonic tics in children and adolescents with Tourette syndrome, in addition to being safe and well tolerated, according to the results of a phase 2b trial presented at the 2022 American Academy of Neurology’s Annual Meeting (AAN 2022).
Novel drug promising for paediatric Tourette syndrome
26 Apr 2022
Does metoprolol influence exercise haemodynamics in HCM?
Exercise contributes to an abnormal risk in pulmonary capillary wedge pressure (PCWP), but is not affected by metoprolol, in patients with obstructive hypertrophic cardiomyopathy (HCM), results of a study have shown.
Does metoprolol influence exercise haemodynamics in HCM?
26 Apr 2022
Ofatumumab boasts long-term safety in relapsing multiple sclerosis
Treatment with ofatumumab in the long term (approximately 3.5 years) among patients with relapsing multiple sclerosis (MS) is well-tolerated, with no new safety risks found, according to the results of ALITHIOS, presented at the 2022 Annual Meeting of the American Academy of Neurology.
Ofatumumab boasts long-term safety in relapsing multiple sclerosis
26 Apr 2022
Ramucirumab–paclitaxel combo works better against HER2-positive vs -negative gastric cancers
Treatment with the combination of ramucirumab and paclitaxel in the second-line setting appears to yield higher responses among patients with HER2-positive gastric or gastro-oesophageal junction adenocarcinoma than among those with HER2-negative disease, according to a subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
